Daily Stock Analysis, ARDX, Ardelyx Inc, priceseries

Ardelyx Inc. Daily Stock Analysis
Stock Information
Open
3.62
Close
3.52
High
3.65
Low
3.33
Previous Close
3.60
Daily Price Gain
-0.08
YTD High
3.90
YTD High Date
Apr 11, 2019
YTD Low
1.70
YTD Low Date
Jan 2, 2019
YTD Price Change
1.52
YTD Gain
76.00%
52 Week High
4.60
52 Week High Date
Aug 29, 2018
52 Week Low
1.60
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-0.88
52 Week Gain
-20.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
4.65
Jul 6. 2017
5.10
12 Trading Days
9.78%
Link
LONG
Nov 16. 2017
5.60
Dec 4. 2017
6.06
11 Trading Days
8.15%
Link
LONG
Dec 19. 2017
6.35
Jan 8. 2018
6.87
12 Trading Days
8.20%
Link
LONG
Jan 4. 2019
2.06
Jan 16. 2019
2.25
8 Trading Days
9.23%
Link
LONG
Feb 6. 2019
2.26
Mar 26. 2019
3.18
33 Trading Days
40.88%
Link
LONG
Apr 4. 2019
3.07
Apr 17. 2019
3.35
9 Trading Days
9.06%
Link
Company Information
Stock Symbol
ARDX
Exchange
NasdaqGM
Company URL
http://www.ardelyx.com
Company Phone
510-745-7047
CEO
Michael G. Raab
Headquarters
California
Business Address
34175 ARDENWOOD BLVD., FREMONT, CA 94555
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001437402
About

Ardelyx, Inc. operates as a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal, tract to treat gastrointestinal and cardio-renal diseases. The company's products include Tenapanor, RDX002, RDX009 and RDX013. Ardelyx was founded by Dominique Charmot, Peter G. Schultz and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Description

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.